Drug reference

Pasireotide

Somatostatin Analogue · Endocrine Agent

Somatostatin AnalogueEndocrine Agent

CDSCO approvedSchedule H

EXCRETION

—

not curated

INTERACTIONS

12 major

SEVERE in our sources

PREGNANCY

Avoid (may impair biosynthesis of fetalplacental steroids).

FDA category + note

Top interactionssee all 12 →

AbarelixSevereDatabaseDDInter
AbirateroneSevereDatabaseDDInter
AdenosineSevereDatabaseDDInter
AlfuzosinSevereDatabaseDDInter

Mechanism

Pasireotide is a synthetic somatostatin analog that binds to and activates somatostatin receptors (SSTRs), particularly SSTR5, with greater affinity than other analogs. Activation of SSTRs, including SSTR2 and SSTR5, inhibits cyclic AMP accumulation and regulates hormone secretion, thereby reducing levels of hormones like growth hormone (GH).

Indications

Cushing's syndromeAcromegalyCushing disease (excessive cortisol production triggered by increases in ACTH release due to a pituitary adenoma) in patients ineligible for pituitary surgery or in whom surgery has failedcushing disease (in patients who are not candidates for surgery or who have recurrent disease)Severe secretory diarrheaCarcinoid tumorsGlucagonomasVIPomasCushing disease

Dosing

Adult: l INDICATIONS AND DOSE Suppression of inflammatory and allergic disorders ▶ BY DEEP INTRAMUSCULAR INJECTION ▶ Adult: 40 mg (max.…

Side effects

Common

DiarrheaNauseaAbdominal painMultiple tiny gallstones (presumably due to decreased gallbladder contraction and bile secretion)BradycardiaQT prolongationHypothyroidism (rare)Significantly worsened glucose toleranceHypocortisolism (in Cushing disease treatment)hyperglycemiatransient GI discomfortGI symptoms

Serious